R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal Article
Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
TL;DR: It is suggested that CMV-seronegative blood products alone prevent most CMV infections and CMV disease in CMv-ser onegative allogeneic BMT recipients, even when the marrow donor is CMVs-seropositive.
Journal ArticleDOI
Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma
Raymond Alexanian,Donna M. Weber,Kay Delasalle,Beverly Carol Handy,Richard E. Champlin,Sergio Giralt +5 more
TL;DR: The limited improvement of lifespan and disease-free survival for those in PR indicated the need for further treatment to achieve CR, the major surrogate marker for long survival.
Journal ArticleDOI
HLA-DP incompatibilities and severe graft-versus-host disease in unrelated bone marrow transplants.
Yoshiro Kato,Yako Mitsuishi,Michael Cecka,Judy Hopfield,Lynn Hunt,Richard E. Champlin,Paul I. Terasaki,James Gajewski +7 more
Journal Article
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications.
Richard E. Champlin,Issa F. Khouri,Paolo Anderlini,Marcos de Lima,Chitra Hosing,John McMannis,Jeffrey J. Molldrem,Naoto T. Ueno,Sergio Giralt +8 more
TL;DR: The use of relatively nontoxic, nonmyeloablative, or reduced-intensity preparative regimens still allows engraftment and the generation of graft-vs-malignancy effects, is potentially curative for susceptible malignancies, and reduces the risk of treatment-related morbidity.
Journal ArticleDOI
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation
TL;DR: The antiemetic regimen of granisetron plus dexamethasone appears effective and well tolerated during BMT conditioning with high-dose cyclophos- phamide and TBI.